Eton Pharmaceuticals Announces Second Quarter 2020 Financial Results
“Recent weeks have been the most productive in our company’s history. We submitted two NDAs, including one with orphan designation, and we made significant progress preparing for our expected launch of Alkindi Sprinkle,” said
Recent Milestones
- Submission of Orphan Drug DS-100 (Dehydrated Alcohol Injection). In July, Eton submitted an NDA for DS-100. The product has been granted orphan drug designation for the treatment of methanol poisoning. The incidence of methanol poisoning has increased significantly in 2020 due to COVID-19, as unprecedented demand for hand sanitizers has led some manufacturers to improperly use methanol in their products. The
U.S. Food and Drug Administration (FDA) has in fact recommended manufacturers recall more than 100 different hand sanitizers that were found to contain methanol despite being labeled as ethanol.
- Submission of ET-104 (Zonisamide Oral Suspension). Eton’s patent-pending liquid formulation of zonisamide was submitted to the FDA for the treatment or partial seizures. ET-104 is one of three neurology-focused liquid products that Eton expects to launch in 2021
- Increased Credit Facility. Eton was able to amend and increase its existing credit facility with SWK Holdings. Under the new terms, the facility will increase from
$10 million to$15 million upon FDA approval of Alkindi Sprinkle, and the interest rate will decrease when Eton achieves certain performance metrics in the future.
EM-100 Update
Eton was notified by its partner that due to a proprietary name change submission, the FDA has extended EM-100’s goal date to
Alkindi® Sprinkle Update
Alkindi Sprinkle’s NDA is under review by the FDA for use as a replacement therapy for pediatric adrenal insufficiency. Eton and its development partner have been engaged in regular communication with the FDA, and Eton expects the FDA to meet the existing
Biorphen Commercial Update
Biorphen sales continue to be impacted by COVID-19. While surgical procedure volumes have rebounded from March and April lows, hospital policies continue to restrict sales representatives from visiting with pharmacy directors and hospital staff. Eton plans to implement new targeting strategies and promotional campaigns in the third quarter that are expected to drive stronger sales in the second half of 2020.
Eton remains confident that there is strong demand for Biorphen in a vial presentation based on significant customer feedback. The company is on pace to submit a Prior Approval Supplement (PAS) for the vial conversion later this year, which should allow for a commercial launch of the vial in early 2021. Eton expects the vial product launch to significantly accelerate Biorphen adoption and help the company achieve its long-term goal of capturing 4 million of the estimated more than 20-million-unit market for ready-to-use phenylephrine injection.
Credit Agreement.
On
Pipeline Update
Eton now has six product candidates submitted to the FDA, and two additional product candidates that are expected to be submitted before the end of 2020.
Product | FDA Application Status | Details |
Biorphen® | Approved | Commercial |
EM-100 (Ketotifen Ophthalmic Soln.) | Submitted | T.A.D |
Alkindi® Sprinkle | Submitted | PDUFA Date: |
DS-100 (Dehydrated Alcohol Inj.) | Submitted | PDUFA date not yet assigned |
ET-105 (Lamotrigine Oral Susp.) | Submitted | CRL response ongoing |
ET-104 (Zonisamide Oral Susp.) | Submitted | PDUFA date not yet assigned |
DS-300 (Cysteine Inj.) | Submitted | GDUFA Date: |
ET-101 (Topiramate Oral Soln.) | Submission Expected in 2020 | |
ET-203 (Ephedrine Inj.) | Submission Expected in 2020 | |
*Potential tentative approval. Final approval expected to be delayed due to ongoing Paragraph IV litigation |
ET-105 (Lamotrigine for Oral Suspension). Eton and its development partner,
ET-101 (Topiramate Oral Solution). Eton remains on track to submit the product’s NDA before year end.
ET-203 (Ephedrine Injection). Eton’s partner expects to file the product’s NDA before year end.
Financial Update
Revenue: Revenue was approximately
Research and Development (R&D) Expenses: R&D expenses were
General& Administrative (G&A) Expenses: G&A expenses were
Net Loss: Eton reported a net loss for the second quarter of 2020 of
Cash Position: As of
Conference Call and Webcast Information:
Eton Pharmaceuticals will host a conference call and webcast today at 4:30 p.m. ET (
About Eton Pharmaceuticals
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Condensed Statements of Operations
(In thousands, except per share amounts)
(Unaudited)
For the three months ended | For the six months ended | ||||||||||||||
2020 | 2019 | 2020 | 2019 | ||||||||||||
Revenues: | |||||||||||||||
Product sales | $ | 20 | $ | — | $ | 119 | $ | — | |||||||
Licensing revenue | — | — | — | 500 | |||||||||||
Total revenues | 20 | — | 119 | 500 | |||||||||||
Cost of product sales | 28 | — | 130 | — | |||||||||||
Gross (loss) profit | (8 | ) | — | (11 | ) | 500 | |||||||||
Operating expenses: | |||||||||||||||
Research and development | 1,609 | 1,439 | 7,877 | 7,904 | |||||||||||
General and administrative | 2,921 | 1,910 | 5,531 | 3,499 | |||||||||||
Total operating expenses | 4,530 | 3,349 | 13,408 | 11,403 | |||||||||||
Loss from operations | (4,538 | ) | (3,349 | ) | (13,419 | ) | (10,903 | ) | |||||||
Other (expense) income: | |||||||||||||||
Interest and other (expense) income, net | (192 | ) | 100 | (360 | ) | 244 | |||||||||
Loss before income tax expense | (4,730 | ) | (3,249 | ) | (13,779 | ) | (10,659 | ) | |||||||
Income tax expense | — | — | — | — | |||||||||||
Net Loss | $ | (4,730 | ) | $ | (3,249 | ) | $ | (13,779 | ) | $ | (10,659 | ) | |||
Net loss per share, basic and diluted | $ | (0.23 | ) | $ | (0.18 | ) | $ | (0.70 | ) | $ | (0.61 | ) | |||
Weighted average number of common shares outstanding, basic and diluted | 21,005 | 17,733 | 19,574 | 17,618 |
Condensed Balance Sheets
(in thousands, except share and per share amounts)
(Unaudited) | ||||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 10,270 | $ | 12,066 | ||||
Accounts receivable, net | — | 473 | ||||||
Inventory | 1,709 | 380 | ||||||
Prepaid expenses and other current assets | 844 | 2,090 | ||||||
Total current assets | 12,823 | 15,009 | ||||||
Property and equipment, net | 938 | 1,117 | ||||||
Intangible assets, net | 650 | 725 | ||||||
Operating lease right-of-use assets, net | 96 | 160 | ||||||
Other long-term assets, net | 52 | 61 | ||||||
Total assets | $ | 14,559 | $ | 17,072 | ||||
Liabilities and stockholders’ equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 1,953 | $ | 575 | ||||
PPP loan, current portion | 159 | — | ||||||
Accrued liabilities | 627 | 1,388 | ||||||
Total current liabilities | 2,739 | 1,963 | ||||||
Long-term debt, net of discount and including accrued fees | 4,587 | 4,540 | ||||||
Long-term portion of PPP loan | 202 | — | ||||||
Operating lease liabilities, net of current portion | — | 19 | ||||||
Total liabilities | 7,528 | 6,522 | ||||||
Commitments and contingencies (Note 11) | ||||||||
Stockholders’ equity | ||||||||
Common stock, 2020 and outstanding at |
21 | 18 | ||||||
Additional paid-in capital | 84,977 | 74,720 | ||||||
Accumulated deficit | (77,967 | ) | (64,188 | ) | ||||
Total stockholders’ equity | 7,031 | 10,550 | ||||||
Total liabilities and stockholders’ equity | $ | 14,559 | $ | 17,072 |
Condensed Statements of Cash Flows
(In thousands)
(Unaudited)
Six months ended |
Six months ended |
|||||||
Cash flows from operating activities | ||||||||
Net loss | $ | (13,779 | ) | $ | (10,659 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Stock-based compensation | 1,079 | 850 | ||||||
Common stock issued for product candidate licensing rights | 1,264 | — | ||||||
Depreciation and amortization | 326 | 178 | ||||||
Debt discount amortization | 50 | — | ||||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | 473 | — | ||||||
Inventory | (1,329 | ) | — | |||||
Prepaid expenses and other assets | 1,251 | (1,052 | ) | |||||
Accounts payable | 1,378 | (69 | ) | |||||
Accrued liabilities | (783 | ) | (211 | ) | ||||
Net cash used in operating activities | (10,070 | ) | (10,963 | ) | ||||
Cash used in investing activities | ||||||||
Purchases of property and equipment | (4 | ) | (1,030 | ) | ||||
Cash flows from financing activities | ||||||||
Proceeds from sales of common stock, net of offering costs | 7,756 | — | ||||||
Proceeds from PPP loan | 361 | — | ||||||
Proceeds from employee stock purchase plan and stock option exercises | 161 | 205 | ||||||
Net cash provided by financing activities | 8,278 | 205 | ||||||
Change in cash and cash equivalents | (1,796 | ) | (11,788 | ) | ||||
Cash and cash equivalents at beginning of period | 12,066 | 26,735 | ||||||
Cash and cash equivalents at end of period | $ | 10,270 | $ | 14,947 | ||||
Supplemental disclosures of cash flow information | ||||||||
Cash paid for interest | $ | 358 | $ | — | ||||
Cash paid for income taxes | $ | — | $ | — |
Investor Contact:
dkrempa@etonpharma.com
612-387-3740
Source: Eton Pharmaceuticals